Genentech · company speakers →
presented studies of GDC-2992, a bifunctional, dual inhibitor of both the wild-type and mutant forms of the androgen receptor that is often expressed aberrantly in prostate cancer.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →